Monday, Aug 6, 2001

Genentech Appoints Andrew C. Chan to Senior Director of Immunology

Howard Hughes Medical Institute Associate Investigator Joins Company to Expand Immunology Program

South San Francisco, Calif. -- August 6, 2001 --

Genentech, Inc. (NYSE: DNA) today announced the appointment of Andrew C. Chan, M.D., Ph.D., to senior director of immunology in Genentech's Research department. Chan will report to Richard H. Scheller, Ph.D., senior vice president, Research.

"Dr. Chan is a preeminent scientist who will be a tremendous asset to Genentech's Research organization," said Scheller. "We are very excited about having someone of his caliber lead the expansion of our program in immunology and look forward to his scientific contributions and leadership."

In his new position, Chan will oversee Genentech's research programs focused on the role of the immune system in cancer and immune disorders. The immune system plays a vital role in the body's defense against foreign pathogens. Abnormal function of the immune system can also trigger these "normal" defense mechanisms and induce "abnormal activation" of immune cells to induce a variety of disorders. Chan's extensive work in immunology has revealed much about the regulatory molecules and mechanisms of the immune system and the factors that contribute to disease.

"I am pleased to be joining a company so deeply committed to innovative research and look forward to working to identify potential therapeutic targets based on research of the immune system," said Chan.

Chan, 41, joins Genentech from Washington University School of Medicine in St. Louis, where he was an associate professor in the Division of Rheumatology and the Departments of Medicine, Pathology and Immunology, and a Howard Hughes Medical Institute (HHMI) associate investigator. HHMI investigators are leading biomedical scientists appointed to serve in prestigious research positions based on their potential to make significant contributions to science.

Chan is a member of several professional organizations including the American Association of Immunologists, the American Society of Microbiology, and the American Society for Clinical Investigation. He serves on the editorial and advisory boards of the Journal of Biological Chemistry and Signal Transduction. Chan is a frequent lecturer and has authored or co-authored more than 50 scientific articles.

Chan received his bachelor's and master's degrees in chemistry from Northwestern University, and his medical degree and doctorate in cellular and developmental biology from the Washington University School of Medicine. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University School of Medicine prior to becoming a postdoctoral clinical and research fellow at the University of California, San Francisco.

Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved products of biotechnology stem from or are based on Genentech science. Genentech markets nine products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #